SK Biopharm Signs Pharmaceutical Supply Contract Worth 66.4 Billion KRW
[Asia Economy Reporter Minji Lee] SK Biopharm announced on the 25th that it has signed a pharmaceutical supply contract worth 66.4 billion KRW with its subsidiary SK Life Science. This amount corresponds to 16% of recent sales revenue.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "It's Only May, but Convenience Stores Know... Iced Americano at 24°C, Tube Ice Cream at 31°C: The Thermometer of the Summer Sales Boom"
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Mother of Three Gang-Raped on Bus in India... Outrage as Bus Driver Implicated
- "I Hated Myself as Much as I Craved It"... Even a Mother's Tears and Brilliant Dreams Were Shattered [ChwiYakGukga] ⑦
The company stated, "This contract is to supply products to SK Life Science, our local subsidiary in the United States, for the sales of the new epilepsy treatment drug Cenobamate in the U.S. market," and added, "This is an internal transaction that is not recorded as sales in the consolidated financial statements."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
